GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Advanced Oncotherapy PLC (LSE:AVO) » Definitions » Beta

Advanced Oncotherapy (LSE:AVO) Beta : 0.28 (As of May. 16, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Advanced Oncotherapy Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-05-16), Advanced Oncotherapy's Beta is 0.28.


Advanced Oncotherapy Beta Historical Data

The historical data trend for Advanced Oncotherapy's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Oncotherapy Beta Chart

Advanced Oncotherapy Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.03 3.09 2.40 0.86 -

Advanced Oncotherapy Semi-Annual Data
Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.08 0.86 - - -

Competitive Comparison of Advanced Oncotherapy's Beta

For the Medical Devices subindustry, Advanced Oncotherapy's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advanced Oncotherapy's Beta Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Advanced Oncotherapy's Beta distribution charts can be found below:

* The bar in red indicates where Advanced Oncotherapy's Beta falls into.



Advanced Oncotherapy Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Advanced Oncotherapy  (LSE:AVO) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Advanced Oncotherapy Beta Related Terms

Thank you for viewing the detailed overview of Advanced Oncotherapy's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Advanced Oncotherapy (LSE:AVO) Business Description

Traded in Other Exchanges
N/A
Address
4 Tenterden Street, Third Floor, London, GBR, W1S 1TE
Advanced Oncotherapy PLC is active in the healthcare domain in the United Kingdom. As a medical care provider, its focus is to develop technologies to maximize the destructive effect of radiation on tumors whilst minimizing damage to healthy tissues. It develops an affordable proton-based radiotherapy system, using innovative and clinically effective technology, thereby contributing to curing critical unmet conditions. The company's only business segment is Proton Therapy.